Health Boards
Sandoz launches first-to-file calcipotriene cream, the first generic.
Sandoz, a Division of the Novartis group, is the second-largest generic pharmaceuticals company globally, offering a broad range of about 1000 high-quality, affordable products that are no longer protected by patents. announces the introduction of its first-to-file calcipotriene cream, the first generic version of LEO Pharma Inc.’s Dovonex® Cream, 0.005% in the US.
"Sandoz is proud to be both the first company to file for and the first to launch this important new generic dermatology medicine, which further strengthens Sandoz’s #1 position in generic dermatology medicines in the US and globally,” said Don DeGolyer, President of Sandoz US. “The launch of calcipotriene cream further demonstrates our commitment to improving patient access to high-quality, affordable medicines.”
According to IMS Health, US sales for the branded version of calcipotriene cream were approximately USD 118.8 million for the 12 months ending in May 2012. Sandoz is marketing calcipotriene in the 0.005% strength, the same strength that is marketed as Dovonex® Cream, 0.005%.
Currently Sandoz has a total of 172 ANDAs (Abbreviated New Drug Applications) pending approval with the US FDA, including 40 confirmed first-to-file opportunities.
Source: sandoz.com
Sandoz, a Division of the Novartis group, is the second-largest generic pharmaceuticals company globally, offering a broad range of about 1000 high-quality, affordable products that are no longer protected by patents. announces the introduction of its first-to-file calcipotriene cream, the first generic version of LEO Pharma Inc.’s Dovonex® Cream, 0.005% in the US.
"Sandoz is proud to be both the first company to file for and the first to launch this important new generic dermatology medicine, which further strengthens Sandoz’s #1 position in generic dermatology medicines in the US and globally,” said Don DeGolyer, President of Sandoz US. “The launch of calcipotriene cream further demonstrates our commitment to improving patient access to high-quality, affordable medicines.”
According to IMS Health, US sales for the branded version of calcipotriene cream were approximately USD 118.8 million for the 12 months ending in May 2012. Sandoz is marketing calcipotriene in the 0.005% strength, the same strength that is marketed as Dovonex® Cream, 0.005%.
Currently Sandoz has a total of 172 ANDAs (Abbreviated New Drug Applications) pending approval with the US FDA, including 40 confirmed first-to-file opportunities.
Source: sandoz.com